Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii

[1]  Y. Yamaoka,et al.  Faculty Opinions recommendation of Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[2]  M. Hattori,et al.  Dysbiosis of the salivary microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a biomarker , 2018, Scientific Reports.

[3]  K. Sugano.  Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date , 2018, Therapeutic advances in gastroenterology.

[4]  Y. Naito,et al.  The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study , 2017, Journal of clinical biochemistry and nutrition.

[5]  C. Elson,et al.  Microbiota , 2010, Gut microbes.

[6]  Wanting Gao,et al.  Characterizing the bacterial microbiota in different gastrointestinal tract segments of the Bactrian camel , 2018, Scientific Reports.

[7]  K. Stingl,et al.  Lactobacillus johnsonii ameliorates intestinal, extra-intestinal and systemic pro-inflammatory immune responses following murine Campylobacter jejuni infection , 2017, Scientific Reports.

[8]  Wei Chen,et al.  Microbial Biogeography and Core Microbiota of the Rat Digestive Tract , 2017, Scientific Reports.

[9]  M. Bonder,et al.  The influence of proton pump inhibitors and other commonly used medication on the gut microbiota , 2017, Gut microbes.

[10]  K. Tominaga,et al.  Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage , 2017, Digestion.

[11]  Y. Naito,et al.  Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals , 2016, Gut.

[12]  M. Nachman,et al.  Spatial Heterogeneity of Gut Microbial Composition along the Gastrointestinal Tract in Natural Populations of House Mice , 2016, PloS one.

[13]  T. Kitazono,et al.  Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  W. Leslie,et al.  A comparison of the gut microbiome between long‐term users and non‐users of proton pump inhibitors , 2016, Alimentary pharmacology & therapeutics.

[15]  Tim D Spector,et al.  Proton pump inhibitors alter the composition of the gut microbiota , 2015, Gut.

[16]  Jingyuan Fu,et al.  Proton pump inhibitors affect the gut microbiome , 2015, Gut.

[17]  Kenji Takahashi,et al.  A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice , 2015, MicrobiologyOpen.

[18]  村木 基子.  Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users , 2015 .

[19]  K. Tominaga,et al.  Association between chronic use of proton pump inhibitors and small- intestinal bacterial overgrowth assessed using lactulose hydrogen breath tests. , 2015, Hepato-gastroenterology.

[20]  Hirokazu Takahashi,et al.  Tu1243 Risk Factors for Small Bowel Mucosal Breaks in Chronic Low-Dose Aspirin Users: Data From a Prospective Multicenter Capsule Endoscopy Registry , 2014 .

[21]  K. Tominaga,et al.  Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users , 2014, Scandinavian journal of gastroenterology.

[22]  K. Tominaga,et al.  High-Mobility Group Box 1 Inhibits Gastric Ulcer Healing through Toll-Like Receptor 4 and Receptor for Advanced Glycation End Products , 2013, PloS one.

[23]  L. Duan,et al.  Bacterial Community Mapping of the Mouse Gastrointestinal Tract , 2013, PloS one.

[24]  Walter Wai-Yip Chan,et al.  Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  K. Tominaga,et al.  Rebamipide inhibits indomethacin-induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of α-defensin 5. , 2013, European journal of pharmacology.

[26]  P. Siersema,et al.  Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia , 2012, Alimentary pharmacology & therapeutics.

[27]  K. Tominaga,et al.  High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4. , 2012, The American journal of pathology.

[28]  Terufumi Takagi,et al.  Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). , 2012, Journal of medicinal chemistry.

[29]  Anil K. Jain,et al.  Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  E. Ongini,et al.  Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. , 2011, Gastroenterology.

[31]  K. Tominaga,et al.  Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[32]  K. Tominaga,et al.  Evaluation of Small Bowel Injury in Patients with Rheumatoid Arthritis by Capsule Endoscopy: Effects of Anti-Rheumatoid Arthritis Drugs , 2009, Digestion.

[33]  F. Schmidt.  Meta-Analysis , 2008 .

[34]  K. Tominaga,et al.  Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent , 2007, Gut.

[35]  Yu-Xiao Yang,et al.  Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.

[36]  B. Lewis,et al.  Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  D. Graham,et al.  Visible small-intestinal mucosal injury in chronic NSAID users. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  Abdulmajeed Al Abdukareem.  Randomized, placebo-controlled trial , 2004, Annals of Saudi medicine.